Thanks Taureanbull. Really appreciate your responses. So in...

Thanks Taureanbull. Really appreciate your responses. So in essence , a phase 2 trial for Dementia and/or Parkinsons would have been much bigger in scale/cost than the 4 indications Neuren decided to move forward with, hence the reason it didnt go any further. I am really hoping money was the only reason for not moving forward, as the potential is amazing if the pre-clinicals get an opportunity to be proven (and is proven) via clinical trials.

The first set of phase 2 trial results have a lot hinging on it! Hopefully the Phelan-McDermid results are conclusive enough for all these other possibilities to become very relevant.